Cargando…

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy

Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brumberg, Joachim, Beckl, Melanie, Dierks, Alexander, Schirbel, Andreas, Krebs, Markus, Buck, Andreas, Kübler, Hubert, Lapa, Constantin, Seitz, Anna Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698713/ https://www.ncbi.nlm.nih.gov/pubmed/33217931 http://dx.doi.org/10.3390/biomedicines8110511

Ejemplares similares

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer
por: Fassbind, Saskia, et al.
Publicado: (2021)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features
por: Zhou, Xiang, et al.
Publicado: (2020)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with [(68)Ga]Ga-PSMA I&T
por: Schumann, Sarah, et al.
Publicado: (2020)

Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
por: Bluemel, Christina, et al.
Publicado: (2016)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Improved cancer detection in Waldeyer’s tonsillar ring by (68)Ga-FAPI PET/CT imaging
por: Serfling, S., et al.
Publicado: (2020)

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
por: Kraus, Sabrina, et al.
Publicado: (2022)

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
por: Linz, Christian, et al.
Publicado: (2021)

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer
por: Ettala, Otto, et al.
Publicado: (2019)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study
por: Hoberück, Sebastian, et al.
Publicado: (2020)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

Impact of Three-Month Androgen Deprivation Therapy on [68Ga]Ga-PSMA-11 PET/CT Indices in Men with Advanced Prostate Cancer—Results from a Pilot Prospective Study
por: Tseng, Jing-Ren, et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT Features Extracted from Different Radiomic Zones Predict Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer
por: Tran, Vuong Thuy, et al.
Publicado: (2022)

Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
por: Lütje, Susanne, et al.
Publicado: (2016)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

(68)Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with(18)F-FDG, calcium burden and risk factors
por: Li, Xiang, et al.
Publicado: (2012)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy
por: Kesler, Mikhail, et al.
Publicado: (2021)

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
por: Lapa, Constantin, et al.
Publicado: (2016)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Letter to the Editor: (68)Ga-PSMA-11 for renal cortical PET imaging
por: Sarikaya, Ismet
Publicado: (2022)

Impact of (68)Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4dn8b30aqh7fvp70nh9f4kop58